Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom ...

Addition of a low-profile device to the Surmodics Pounce™ thrombectomy platform allows for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee ...

Endologix will market the system to vascular interventionists who use its other devices to treat peripheral artery disease ...

Surmodics has initiated a full commercial release of its Pounce XL thrombectomy system for acute or chronic clot removal. Available through a limited market release since January 2025, Pounce XL ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the ...